達安基因(002030.SZ):目前公司已經有化學發光產品,正在完成整個產品線的配套
格隆匯11月2日丨達安基因(002030.SZ)於2023年11月1日接受特定對象調研,就“近幾年受相關政策的影響,市場對國產替代的化學發光產品的關注度比較高,國內很多公司也在開發相關產品。後疫情時代,公司的發力重點會放在這方面嗎?”,公司回覆稱,目前公司已經有化學發光產品,正在完成整個產品線的配套。公司已全面進入IVD全領域,聚焦於診斷技術和產品的臨牀、公共衞生、檢驗檢疫、生命健康相關領域等全場景應用,將繼續做大做強PCR及分子診斷技術、產品和市場領域,積極發展免疫、生化、分析儀器等全診斷技術平台、產品和市場領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.